The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications
Open accessAbstract
Affibody molecules are a class of engineered affinity proteins with proven potential for therapeutic, diagnostic and biotechnological applications. Affibody molecules are small (6.5 kDa) single domain proteins that can be isolated for high affinity and specificity to any given protein target. Fifteen years after its discovery, the Affibody technology is gaining use in many groups as a tool for creating molecular specificity wherever a small, engineering compatible tool is warranted. Here we summarize recent results using this technology, propose an Affibody nomenclature and give an overview of different HER2‐specific Affibody molecules. Cumulative evidence suggests that the three helical scaffold domain used as basis for these molecules is highly suited to create a molecular affinity handle for vastly different applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synthetic IgG-binding domain based on staphylococcal protein A
Nilsson, B., Moks, T., Jansson, B., Abrahmsén, L., Elmblad, A., Holmgren, E., Henrichson, C., Jones, T. A., & Uhlén, M. (1987) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/1.2.107 · Cited by 759
Engineering novel binding proteins from nonimmunoglobulin domains
Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676
Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain
Nord, K., Gunneriusson, E., Ringdahl, J., Ståhl, S., Uhlén, M., & Nygren, P.-Å. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-772 · Cited by 662
Self-citationTumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule
Orlova, A., Magnusson, M., Eriksson, T. L. J., Nilsson, M., Larsson, B., Höidén-Guthenberg, I., Widström, C., Carlsson, J., Tolmachev, V., Ståhl, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3521 · Cited by 568
Self-citationUhlén, M., Guss, B., Nilsson, B., Gatenbeck, S., Philipson, L., & Lindberg, M. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43463-6 · Cited by 566
Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1891 · Cited by 528
New approaches for imaging tumour responses to treatment
Brindle, K. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2289 · Cited by 460
Stabilization of a β-hairpin in monomeric Alzheimer's amyloid-β peptide inhibits amyloid formation
Hoyer, W., Grönwall, C., Jonsson, A., Ståhl, S., & Härd, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711731105 · Cited by 410
Self-citationTargeted therapy of cancer with radiolabeled antibodies.
Goldenberg, D. M. (2002) · PubMed · Cited by 318
Baum, R. P., Prasad, V., Müller, D., Schuchardt, C., Orlova, A., Wennborg, A., Tolmachev, V., & Feldwisch, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073239 · Cited by 308
Self-citationA combinatorial library of an α-helical bacterial receptor domain
Nord, K., Nilsson, J., Nilsson, B., Uhlén, M., & Nygren, P.-Å. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.6.601 · Cited by 285
Nygren, P. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06438.x · Cited by 282
Zahnd, C., Kawe, M., Stumpp, M. T., de Pasquale, C., Tamaskovic, R., Nagy-Davidescu, G., Dreier, B., Schibli, R., Binz, H. K., Waibel, R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2724 · Cited by 245
Tolmachev, V., Orlova, A., Pehrson, R., Galli, J., Baastrup, B., Andersson, K., Sandström, M., Rosik, D., Carlsson, J., Lundqvist, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1630 · Cited by 220
Self-citationBinding proteins from alternative scaffolds
Nygren, P.-Å., & Skerra, A. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.04.006 · Cited by 218
Preorganized secondary structure as an important determinant of fast protein folding.
Myers, J. K., & Oas, T. G. (2001) · Nature Structural Biology · doi:10.1038/88626 · Cited by 215
Orlova, A., Tolmachev, V., Pehrson, R., Lindborg, M., Tran, T., Sandström, M., Nilsson, F. Y., Wennborg, A., Abrahmsén, L., & Feldwisch, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2887 · Cited by 193
Self-citationDesign of an Optimized Scaffold for Affibody Molecules
Feldwisch, J., Tolmachev, V., Lendel, C., Herne, N., Sjöberg, A., Larsson, B., Rosik, D., Lindqvist, E., Fant, G., Höidén-Guthenberg, I., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.002 · Cited by 181
Self-citationAffibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging
Lee, S. B., Hassan, M., Fisher, R., Chertov, O., Chernomordik, V., Kramer-Marek, G., Gandjbakhche, A., & Capala, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4076 · Cited by 171
HER‐2‐Targeted Nanoparticle–Affibody Bioconjugates for Cancer Therapy
Alexis, F., Basto, P., Levy‐Nissenbaum, E., Radovic‐Moreno, A. F., Zhang, L., Pridgen, E., Wang, A. Z., Marein, S. L., Westerhof, K., Molnar, L. K., et al. (2008) · ChemMedChem · doi:10.1002/cmdc.200800122 · Cited by 164
Kramer-Marek, G., Kiesewetter, D. O., Martiniova, L., Jagoda, E., Lee, S. B., & Capala, J. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0658-0 · Cited by 160
Affibody molecules: potential forin vivoimaging of molecular targets for cancer therapy
Максимилианович, Т. В., Orlova, A., Nilsson, F. Y., Feldwisch, J., Wennborg, A., & Abrahmsén, L. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.4.555 · Cited by 143
Self-citationSelection and characterization of Affibody ligands binding to Alzheimer amyloid β peptides
Grönwall, C., Jonsson, A., Lindström, S., Gunneriusson, E., Ståhl, S., & Herne, N. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.09.013 · Cited by 137
Self-citationМаксимилианович, Т. В., Rosik, D., Wållberg, H., Sjöberg, A., Sandström, M., Hansson, M., Wennborg, A., & Orlova, A. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1283-x · Cited by 118
Nord, K., Nord, O., Uhlén, M., Kelley, B. D., Ljungqvist, C., & Nygren, P. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02344.x · Cited by 117
Максимилианович, Т. В., Nilsson, F. Y., Widström, C., Andersson, K., Rosik, D., Gedda, L., Wennborg, A., & Orlova, A. (2006) · PubMed · Cited by 111
Puri, A., Krämer-Marek, G., Campbell-Massa, R., Yavlovich, A., Tele, S. C., Lee, S., Clogston, J. D., Patri, A. K., Blumenthal, R. P., & Capala, J. (2008) · Journal of Liposome Research · doi:10.1080/08982100802457377 · Cited by 102
Ahlgren, S., Orlova, A., Wållberg, H., Hansson, M., Sandström, M., Lewsley, R., Wennborg, A., Abrahmsén, L., Максимилианович, Т. В., & Feldwisch, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073346 · Cited by 97
Self-citationAdams, G. P., Shaller, C. C., Dadachova, E., Simmons, H. H., Horak, E. M., Tesfaye, A., Klein–Szanto, A. J., Marks, J. D., Brechbiel, M. W., & Weiner, L. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2382 · Cited by 87
Protein scaffold-based molecular probes for cancer molecular imaging
Miao, Z., Levi, J., & Cheng, Z. (2010) · Amino Acids · doi:10.1007/s00726-010-0503-9 · Cited by 84
Sequestration of the Aβ Peptide Prevents Toxicity and Promotes Degradation In Vivo
Luheshi, L. M., Hoyer, W., de Barros, T. P., Härd, I. V. D., Brorsson, A., Macao, B., Persson, C., Crowther, D. C., Lomas, D. A., Ståhl, S., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000334 · Cited by 79
Self-citationNordberg, E., Friedman, M., Göstring, L., Adams, G. P., Brismar, H., Nilsson, F. Y., Ståhl, S., Glimelius, B. L. G., & Carlsson, J. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.05.010 · Cited by 79
Self-citationRapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries
Amstutz, P., Koch, H., Binz, H. K., Deuber, S. A., & Plückthun, A. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl004 · Cited by 77
Zieliński, R., Lyakhov, I. G., Jacobs, A., Chertov, O., Krämer-Marek, G., Francella, N., Stephen, A. G., Fisher, R. J., Blumenthal, R. P., & Capala, J. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ad4d5d · Cited by 72
Engineering and characterization of a bispecific HER2 × EGFR‐binding affibody molecule
Friedman, M., Lindström, S., Ekerljung, L., Svahn, H. A., Carlsson, J., Brismar, H., Gedda, L., Frejd, F. Y., & Ståhl, S. (2009) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20090096 · Cited by 70
Self-citationUpdate: Affibody Molecules for Molecular Imaging and Therapy for Cancer
Orlova, A., Feldwisch, J., Abrahmsén, L., & Максимилианович, Т. В. (2007) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2006.004-u · Cited by 69
Self-citationGong, H., Kovar, J. L., Little, G., Chen, H., & Olive, D. M. (2010) · Neoplasia · doi:10.1593/neo.91446 · Cited by 68
Koch, H., Gräfe, N., Schiess, R., & Plückthun, A. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.12.043 · Cited by 62
Tolmachev, V., Mume, E., Sjöberg, S., Frejd, F., & Orlova, A. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-1003-y · Cited by 61
Self-citationApplication of PET/CT in the Development of Novel Anticancer Drugs
Boss, D. S., Olmos, R. A. V., Sinaasappel, M., Beijnen, J. H., & Schellens, J. H. M. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0097 · Cited by 60
Belousova, N., Mikheeva, G., Gelovani, J. G., & Krasnykh, V. N. (2007) · Journal of Virology · doi:10.1128/jvi.01896-07 · Cited by 56
Beuttler, J., Rothdiener, M., Müller, D., Frejd, F. Y., & Kontermann, R. E. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900061v · Cited by 53
Self-citationAffibody‐mediated transferrin depletion for proteomics applications
Grönwall, C., Sjöberg, A., Ramström, M., Höidén‐Guthenberg, I., Hober, S., Jonasson, P., & Ståhl, S. (2007) · Biotechnology Journal · doi:10.1002/biot.200700053 · Cited by 50
Self-citationCanine, B., Wang, Y., & Hatefi, A. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.04.017 · Cited by 46
Li, J., Lundberg, E. K., Vernet, E., Larsson, B., Höidén‐Guthenberg, I., & Gräslund, T. (2010) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20090226 · Cited by 43
Zbasic—A novel purification tag for efficient protein recovery
Hedhammar, M., & Hober, S. (2007) · Journal of Chromatography A · doi:10.1016/j.chroma.2007.05.091 · Cited by 39
MR molecular imaging of HER‐2 in a murine tumor xenograft by SPIO labeling of anti‐HER‐2 affibody
Kinoshita, M., Yoshioka, Y., Okita, Y., Hashimoto, N., & Yoshimine, T. (2010) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.363 · Cited by 37
Rönnmark, J., Kampf, C., Asplund, A., Höidén‐Guthenberg, I., Wester, K., Pontén, F., Uhlén, M., & Nygren, P. (2003) · Journal of Immunological Methods · doi:10.1016/j.jim.2003.06.001 · Cited by 36
Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector
Myhre, S., Henning, P., Granio, O., Tylö, A. S., Nygren, P., Olofsson, S. ‐., Boulanger, P. A., Lindholm, L., & Hong, S.-S. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302875 · Cited by 27
Selection and characterization of Affibody® ligands to the transcription factor c‐Jun
Lundberg, E. K., Brismar, H., & Gräslund, T. (2008) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20070178 · Cited by 24
Generation of Affibody® ligands binding interleukin‐2 receptor α/CD25
Grönwall, C., Snelders, E., Palm, A. J., Eriksson, F., Herne, N., & Ståhl, S. (2008) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20070261 · Cited by 23
Self-citationVernet, E., Lundberg, E. K., Friedman, M., Rigamonti, N., Klausing, S., Nygren, P., & Gräslund, T. (2009) · New Biotechnology · doi:10.1016/j.nbt.2009.02.001 · Cited by 5
Cited by
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
Contrast agents for molecular photoacoustic imaging
Weber, J., Beard, P. C., & Bohndiek, S. E. (2016) · Nature Methods · doi:10.1038/nmeth.3929 · Cited by 1,270
Harnessing albumin as a carrier for cancer therapies
Hoogenboezem, E. N., & Duvall, C. L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.011 · Cited by 610
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 468
Metadata
- Authors
- Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S., & Frejd, F. Y.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2010-04-11
- Volume
- 584
- Issue
- 12
- Pages
- 2670-2680
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W2077787026
- Cited by
- 651
- References
- 52
- FWCI
- 28.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.